Subtopic Deep Dive
Potassium Homeostasis in Heart Failure
Research Guide
What is Potassium Homeostasis in Heart Failure?
Potassium homeostasis in heart failure refers to the maintenance of serum potassium levels within normal ranges amid dysregulation from neurohormonal activation, renal impairment, and therapies like RAAS inhibitors in HFrEF and HFpEF patients.
Dysregulated potassium balance in heart failure links to arrhythmias and mortality, with hyperkalemia risks elevated by spironolactone and ACE inhibitors. Key trials like PEARL-HF (Pitt et al., 2011, 427 citations) tested polymeric binders such as RLY5016 to prevent hyperkalemia. Meta-analyses confirm U-shaped potassium-outcome risks across kidney function (Kövesdy et al., 2018, 312 citations). Over 1,600 citations span 18 provided papers.
Why It Matters
Stabilizing potassium enables RAAS inhibitor use, cutting mortality in heart failure cohorts; PEARL-HF showed RLY5016 prevented hyperkalemia during spironolactone therapy (Pitt et al., 2011). Abnormal potassium predicts adverse outcomes across eGFR levels, guiding electrolyte monitoring (Kövesdy et al., 2018). SGLT2 inhibitors lower hyperkalemia risk in diabetes with CKD, expanding therapy options (Neuen et al., 2022). Deep learning ECG models screen for hyperkalemia non-invasively (Galloway et al., 2019). These advances optimize guideline-directed medical therapy, improving survival.
Key Research Challenges
Hyperkalemia from RAAS Inhibitors
RAAS inhibitors like spironolactone raise hyperkalemia risk in HF patients with CKD, limiting therapy adherence. PEARL-HF trial tested RLY5016 binder to enable continued spironolactone use (Pitt et al., 2011). Balancing benefits against arrhythmia risks persists (Ferreira et al., 2020).
U-Shaped Potassium Outcome Risk
Both hypo- and hyperkalemia associate with mortality across kidney function, complicating target ranges. CKD Prognosis Consortium meta-analysis quantified risks in outpatients (Kövesdy et al., 2018). HF-specific mechanisms amplify this pattern (Urso et al., 2015).
Non-Invasive Detection Gaps
Routine labs miss dynamic potassium shifts; ECG-based AI screening achieves AUC 0.853-0.883 for hyperkalemia (Galloway et al., 2019). Validation in diverse HF cohorts remains needed. Integrating with biomarkers challenges clinical workflows (Ferreira et al., 2020).
Essential Papers
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
Bertram Pitt, Stefan D. Anker, David A. Bushinsky et al. · 2011 · European Heart Journal · 427 citations
RLY5016 prevented hyperkalaemia and was relatively well tolerated in patients with HF receiving standard therapy and spironolactone (25-50 mg/day).
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
Csaba P. Kövesdy, Kunihiro Matsushita, Yingying Sang et al. · 2018 · European Heart Journal · 312 citations
Outpatient potassium levels both above and below the normal range are consistently associated with adverse outcomes, with similar risk relationships across eGFR and albuminuria.
Development and Validation of a Deep-Learning Model to Screen for Hyperkalemia From the Electrocardiogram
Conner Galloway, Alexander Valys, Jacqueline Baras Shreibati et al. · 2019 · JAMA Cardiology · 302 citations
In this study, using only 2 ECG leads, a deep-learning model detected hyperkalemia in patients with renal disease with an AUC of 0.853 to 0.883. The application of artificial intelligence to the EC...
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment
Massimo Volpe, M Carnovali, Vittoria Mastromarino · 2015 · Clinical Science · 291 citations
After its discovery in the early 1980s, the natriuretic peptide (NP) system has been extensively characterized and its potential influence in the development and progression of heart failure (HF) h...
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L. Neuen, Megumi Oshima, Rajiv Agarwal et al. · 2022 · Circulation · 233 citations
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which impr...
Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure
Tsering Dhondup, Qi Qian · 2017 · Blood Purification · 193 citations
The kidneys play a pivotal role in the regulation of electrolyte and acid-base balance. With progressive loss of kidney function, derangements in electrolytes and acid-base inevitably occur and con...
Abnormalities of Potassium in Heart Failure
João Pedro Ferreira, Javed Butler, Patrick Rossignol et al. · 2020 · Journal of the American College of Cardiology · 161 citations
Reading Guide
Foundational Papers
Start with PEARL-HF trial (Pitt et al., 2011, 427 citations) for binder efficacy in spironolactone-treated HF; follow with Ferreira et al. (2020, 161 citations) for comprehensive potassium abnormalities overview.
Recent Advances
Study Kövesdy et al. (2018, 312 citations) meta-analysis on outcome risks; Galloway et al. (2019, 302 citations) ECG model; Neuen et al. (2022, 233 citations) SGLT2 effects.
Core Methods
Clinical trials (PEARL-HF double-blind RCT); meta-analyses (CKD Prognosis Consortium); deep learning on ECG (2-lead CNN, AUC 0.853-0.883); RAAS inhibition with binders (RLY5016 polymeric).
How PapersFlow Helps You Research Potassium Homeostasis in Heart Failure
Discover & Search
Research Agent uses searchPapers and citationGraph on 'potassium homeostasis heart failure' to map PEARL-HF trial (Pitt et al., 2011) as central node with 427 citations, linking to Ferreira et al. (2020) abnormalities review. exaSearch uncovers hidden meta-analyses like Kövesdy et al. (2018); findSimilarPapers expands to SGLT2 effects (Neuen et al., 2022).
Analyze & Verify
Analysis Agent applies readPaperContent to extract hyperkalemia incidence from PEARL-HF abstract, then verifyResponse with CoVe chain-of-verification flags contradictions across Pitt et al. (2011) and Kövesdy et al. (2018). runPythonAnalysis in sandbox performs GRADE grading on evidence quality for RAAS risks and plots U-shaped curves from meta-analysis data. Statistical verification confirms AUC values from ECG model (Galloway et al., 2019).
Synthesize & Write
Synthesis Agent detects gaps in binder therapy post-PEARL-HF via contradiction flagging between Pitt et al. (2011) and recent SGLT2 data (Neuen et al., 2022), generating exportMermaid diagrams of potassium regulation pathways. Writing Agent uses latexEditText and latexSyncCitations to draft HF electrolyte review sections citing 10+ papers, with latexCompile producing camera-ready manuscript featuring latexGenerateFigure for risk curves.
Use Cases
"Extract potassium level data from PEARL-HF and plot hyperkalemia rates vs placebo."
Research Agent → searchPapers(PEARL-HF) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot of incidence rates from abstract data) → matplotlib figure of RLY5016 efficacy.
"Write LaTeX review on potassium binders in HF with citations from Pitt and Ferreira."
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft sections) → latexSyncCitations(10 papers) → latexCompile → PDF with integrated bibliography.
"Find GitHub repos analyzing ECG deep learning for hyperkalemia like Galloway 2019."
Research Agent → paperExtractUrls(Galloway et al.) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified code for ECG model replication.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ potassium-HF papers via searchPapers → citationGraph → GRADE synthesis, outputting structured report on RAAS risks citing Kövesdy (2018). DeepScan applies 7-step analysis with CoVe checkpoints to validate ECG screening claims from Galloway (2019). Theorizer generates hypotheses on SGLT2 potassium mechanisms from Neuen (2022) and Ferreira (2020).
Frequently Asked Questions
What defines potassium homeostasis in heart failure?
It involves regulating serum potassium amid HF-induced renal impairment and RAAS inhibitor effects, preventing hypo- and hyperkalemia-linked arrhythmias.
What methods prevent hyperkalemia in HF?
Polymeric binders like RLY5016 in PEARL-HF trial reduced hyperkalemia during spironolactone therapy (Pitt et al., 2011). SGLT2 inhibitors lower risk in diabetic CKD (Neuen et al., 2022).
What are key papers on this topic?
PEARL-HF trial (Pitt et al., 2011, 427 citations) on binders; CKD meta-analysis (Kövesdy et al., 2018, 312 citations) on U-shaped risks; ECG AI model (Galloway et al., 2019, 302 citations); HF abnormalities review (Ferreira et al., 2020, 161 citations).
What open problems exist?
Optimal potassium targets in HFpEF vs HFrEF; prospective ECG AI validation beyond renal cohorts; long-term binder safety with SGLT2 and RAAS combinations.
Research Potassium and Related Disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Potassium Homeostasis in Heart Failure with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Potassium and Related Disorders Research Guide